Journal of Community Genetics · 18 Nov 2026
Clinical and hematological characterization and carrier status awareness in a colombian cohort of sickle cell trait: a multicenter study
Yusselfy Márquez-Benítez, Jaime Bernal-Villegas, Valeria Isabela Osorio-Garzón, Eduardo Alberto Rojas-Vergara, Escilda Benavides-Benítez, Ignacio Briceño-Balcázarh-index 15
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Background Sickle cell trait (SCT) has traditionally been categorized as a benign carrier state; however, isolated reports and case series have nonetheless described rare complications overlapping with those seen in sickle cell disease (HbSS). The strength and consistency of these associations remain incompletely characterized. In this context, public health institutions like the Centers for Disease Control and Prevention (CDC) have emphasized the need to expand research on SCT. Objective To characterize the clinical and hematological profile of HbAS carriers compared with HbAA individuals and to assess carrier status awareness within a Colombian cohort. Methods A descriptive and analytical cross-sectional study was conducted among 400 adult volunteers from the Pacific and Atlantic Afro-descendant regions. Genotypes were confirmed via high-precision liquid chromatography (HPLC) and rs334 SNP sequencing. Clinical data were retrieved through structured interviews and medical record reviews. Hematological parameters and comorbidities were compared between HbAS and HbAA individuals using robust statistical analysis. Results A significant genotype unawareness was identified, with 45.9% (95%CI: 37.3%–54.8%; n = 56/122) of HbAS carriers being uninformed of their status prior to screening. Serious clinical events were documented predominantly in the HbAS group: Osteomyelitis and atypical diaphyseal femoral osteonecrosis occurred only in carriers (3.3% vs. 0.0%, Fisher´s exact p = 0.016). Neurovascular events; showed a higher prevalence in heterozygous individuals (5.7% vs. 0.9%, p = 0.013). The vast majority of HbAS carriers presented at the time of this project, percentage of HbS 36–40%. Regarding hematological parameters, HbAS individuals exhibited lower mean levels of RDW (12.2 ± 0.7% vs. 13.4 ± 1.3%, p = 0.017), platelets (260 ± 56.4 × 10 9 /L vs. 308.2 ± 95.8 × 10 9 /L, p = 0.003), and white blood cell count (6.1 ± 1.5 × 10 9 /L vs. 7.4 ± 1.8 × 10 9 /L, p = 0.026) compared to non-carrier individuals (HbAA). Conclusion These findings suggest that HbAS may not be uniformly benign, as uncommon but clinically notable vaso-occlusive and osteonecrotic events were observed in a minority of carriers, alongside statistically detectable but subclinical hematological differences and a substantial gap in genotype awareness. Given the cross-sectional design and the small number of severe events, these findings should be considered hypothesis-generating rather than confirmatory. Larger longitudinal studies are needed to clarify their clinical significance and to inform screening and monitoring strategies in high-prevalence populations.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Ignacio Briceño-Balcázar has the highest h-index among the authors (15).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (44)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 24 more references
A free account opens the rest of the citing papers and references on every paper’s page.